Assessing Genetic Risk for IgA Nephropathy

Prakash, Sindhuri; Gharavi, Ali G.

doi:10.2215/cjn.19491220

Cited by 4 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its prevalence closely parallels the variation in local pathogens, suggesting a multi-locus adaptation to helminthic diversity [2]. GWAS have also implicated risk loci and candidate genes involved in antigen presentation, gut mucosal immunity, IgA biology and immune dysregulation of the alternative complement system in IgAN [44] and hence exposing possible targets for new interventions. As is common among GWAS though, these identified loci typically have small effect sizes, explaining only 6-8% of the overall disease risk [2].…”

Section: Genetic Basis Of Iganmentioning

confidence: 99%

Recurrent Immunoglobulin A Nephropathy after Kidney Transplant—An Updated Review

Han,

Lubetzky,

Anandasivam

et al. 2023

Transplantology

View full text Add to dashboard Cite

Immunoglobulin A nephropathy (IgAN) is the commonest glomerulonephritis worldwide, a category that represents the third most frequent cause of end-stage kidney disease (ESKD) in the United States. Kidney transplantation remains the optimal treatment of ESKD, and yet the prospects of IgAN recurrence post-transplant dampens the enthusiasm for living kidney donation in some instances, in addition to limiting the longevity of the kidney allograft. Moreover, the lack of a standardized method for detecting IgAN recurrence, since not all centers perform protocol allograft biopsies, has led to an underestimation of the extent of the issue. The pathogenesis of de novo IgAN remains conjectural, let alone the pathways for recurrent disease, but is increasingly recognized as a multi-hit injury mechanism. Identification of recurrent disease rests mainly on clinical symptoms and signs (e.g., hematuria, proteinuria) and could only be definitively proven with histologic evidence which is invasive and prone to sampling error. Treatment had relied mainly on nonspecific goals of proteinuria reduction, and in some cases, immunosuppression for active, crescentic disease. More recently, newer targets have the potential to widen the armamentarium for directed therapies, with more studies on the horizon. This review article provides an update on recurrent IgAN post-transplant.

show abstract

Section: Genetic Basis Of Iganmentioning

confidence: 99%